Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Confirmation of 123I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders

Daniela D. Maltais, Lennon G. Jordan, Hoon-Ki Min, Toji Miyagawa, Scott Pryzbleski, Timothy G. Lesnick, Robert Ross Reichard, Dennis W. Dickson, Melissa E. Murray, Kejal Kantarci, Bradley F. Boeve and Val Lowe
Journal of Nuclear Medicine May 2020, jnumed.119.239418; DOI: https://doi.org/10.2967/jnumed.119.239418
Daniela D. Maltais
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lennon G. Jordan III
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hoon-Ki Min
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toji Miyagawa
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Pryzbleski
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy G. Lesnick
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Ross Reichard
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis W. Dickson
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa E. Murray
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kejal Kantarci
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley F. Boeve
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Val Lowe
Mayo Clinic, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Rationale: To conduct a retrospective study comparing three 123I-FP-CIT-SPECT quantitative methods in patients with neurodegenerative syndromes as referenced to neuropathological findings. Methods: 123I-FP-CIT-SPECT and neuropathological findings among patients with neurodegenerative syndromes from the Mayo Alzheimer's Disease Research Center and Mayo Clinic Study of Aging were examined. Three 123I-FP-CIT-SPECT quantitative assessment Methods: MIMneuro (MIM Software Inc.), DaTQUANT (GE Healthcare), and manual region of interest (ROI) creation on an Advantage Workstation (GE Healthcare) were compared to neuropathological findings describing the presence or absence of Lewy body disease (LBD). Striatum to background ratios (SBRs) generated by DaTQUANT were compared to the calculated SBRs of the manual method and MIMneuro. The left and right SBRs for caudate, putamen and striatum were evaluated with the manual method. For DaTQUANT and MIMneuro the left, right, total and average SBRs and z-scores for whole striatum, caudate, putamen, anterior putamen, and posterior putamen were calculated. Results: The cohort included 24 patients [20 (83%) male, aged 75.4 +/- 10.0 at death]. The antemortem clinical diagnoses were Alzheimer’s disease dementia (ADem, N = 6), probable dementia with Lewy bodies (pDLB, N = 12), mixed ADem/pDLB (N = 1), Parkinson’s disease with mild cognitive impairment (N = 2), corticobasal syndrome (N = 1), idiopathic rapid eye movement sleep behavior disorder (iRBD) (N = 1) and behavioral variant frontotemporal dementia (N = 1). Seventeen (71%) had LBD pathology. All three 123I-FP-CIT-SPECT quantitative methods had area under the receiver operating characteristics (AUROC) values above 0.93 and up to 1.000 (p<0.001) and showed excellent discrimination between LBD and non-LBD patients in each region assessed, p<.001. There was no significant difference between the accuracy of the regions in discriminating the two groups, with good discrimination for both caudate and putamen. Conclusion: All three 123I-FP-CIT-SPECT quantitative methods showed excellent discrimination between LBD and non-LBD patients in each region assessed, using both SBRs and z-scores.

  • Neurology
  • PET/CT
  • Statistical Analysis
  • 123I-FP-CIT SPECT
  • 123I-ioflupane
  • Dementia with Lewy body
  • Lewy body disease
  • neuropathology
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Confirmation of 123I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Confirmation of 123I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders
Daniela D. Maltais, Lennon G. Jordan, Hoon-Ki Min, Toji Miyagawa, Scott Pryzbleski, Timothy G. Lesnick, Robert Ross Reichard, Dennis W. Dickson, Melissa E. Murray, Kejal Kantarci, Bradley F. Boeve, Val Lowe
Journal of Nuclear Medicine May 2020, jnumed.119.239418; DOI: 10.2967/jnumed.119.239418

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Confirmation of 123I-FP-CIT-SPECT (ioflupane) quantification methods in dementia with Lewy body and other neurodegenerative disorders
Daniela D. Maltais, Lennon G. Jordan, Hoon-Ki Min, Toji Miyagawa, Scott Pryzbleski, Timothy G. Lesnick, Robert Ross Reichard, Dennis W. Dickson, Melissa E. Murray, Kejal Kantarci, Bradley F. Boeve, Val Lowe
Journal of Nuclear Medicine May 2020, jnumed.119.239418; DOI: 10.2967/jnumed.119.239418
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Neurology)

  • Predicting the Outcome of Epilepsy Surgery by Covariance Pattern Analysis of Ictal Perfusion SPECT
  • Postinfectious Neurologic Complications in COVID-19: A Complex Case Report
Show more Clinical (Neurology)

Similar Articles

Keywords

  • Neurology
  • PET/CT
  • Statistical Analysis
  • 123I-FP-CIT SPECT
  • 123I-ioflupane
  • Dementia with Lewy body
  • Lewy body disease
  • neuropathology
SNMMI

© 2025 SNMMI

Powered by HighWire